Literature DB >> 10787120

Localized lipoatrophy after prolonged treatment with copolymer 1.

G L Mancardi, A Murialdo, F Drago, C Brusati, R Croce, M Inglese, S Ratto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10787120     DOI： 10.1007/s004150050568

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  6 in total

1.  Lipoatrophy: a non-reversible complication of subcutaneous interferon-beta 1a treatment of multiple sclerosis.

Authors:  Antonie Giaever Beiske; Kjell-Morten Myhr
Journal:  J Neurol       Date:  2006-03-06       Impact factor: 4.849

2.  Necrotising cutaneous lesions as a side effect of glatiramer acetate.

Authors:  Isabel Bosca; Maria Bosca; Antonio Belenguer; Monserrat Evole; Miguel Hernandez; Bonaventura Casanova; Francisco Coret
Journal:  J Neurol       Date:  2006-06-13       Impact factor: 4.849

3.  Risk-benefit assessment of glatiramer acetate in multiple sclerosis.

Authors:  T Ziemssen; O Neuhaus; R Hohlfeld
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 4.  US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles.

Authors:  Steven L Galetta; Clyde Markowitz
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 5.  Cutaneous Adverse Effects of Neurologic Medications.

Authors:  Eman Bahrani; Chloe E Nunneley; Sylvia Hsu; Joseph S Kass
Journal:  CNS Drugs       Date:  2016-03       Impact factor: 6.497

6.  Is metabolic flexibility altered in multiple sclerosis patients?

Authors:  Anja Mähler; Jochen Steiniger; Markus Bock; Alexander U Brandt; Verena Haas; Michael Boschmann; Friedemann Paul
Journal:  PLoS One       Date:  2012-08-28       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.